OncoTherapy Science, Inc. (4564.T)
JPY 26.0
(-3.7%)
JPY 26.0
(-3.7%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 610.11 Million | 1.13 Billion | 1.15 Billion | 332.47 Million | 316.21 Million | 280.58 Million |
| Cost of Revenue | 787.83 Million | 1.09 Billion | 1.03 Billion | 312.93 Million | 366.33 Million | 2.82 Billion |
| Gross Profit | -177.71 Million | 41.68 Million | 113.91 Million | 19.54 Million | -50.11 Million | -2.54 Billion |
| Operating Expenses | 943.08 Million | 1.14 Billion | 2.16 Billion | 1.65 Billion | 2.13 Billion | 3.23 Billion |
| Selling, General and Administrative Expenses | 265.03 Million | 431.63 Million | 436.27 Million | 281.79 Million | 397.37 Million | 407.72 Million |
| Research and Development Expenses | 678.05 Million | 716.46 Million | 1.73 Billion | 1.37 Billion | 1.74 Billion | 2.82 Billion |
| Other Expenses | - | -15.8 Million | 611 Thousand | 1.34 Million | 70 Thousand | -107.17 Million |
| Cost and Expenses | 1.73 Billion | 2.24 Billion | 3.2 Billion | 1.97 Billion | 2.5 Billion | 3.23 Billion |
| Operating Income | -1.12 Billion | -1.1 Billion | -2.05 Billion | -1.63 Billion | -2.18 Billion | -2.95 Billion |
| Interest Expense | 218 Thousand | - | - | - | - | - |
| Income Tax Expense | 2.42 Million | 2.22 Million | 1.23 Million | 1.62 Million | 1.56 Million | -2.84 Million |
| Earnings before Tax | -1.28 Billion | -1.11 Billion | -2.57 Billion | -1.56 Billion | -2.23 Billion | -3.19 Billion |
| Net Income | -1.28 Billion | -1.11 Billion | -2.57 Billion | -1.56 Billion | -2.23 Billion | -2.93 Billion |
| Earnings Per Share Basic | -6.05 | -5.81 | -13.72 | -8.86 | -13.73 | -19.90 |
| Earnings Per Share Diluted | -6.05 | -5.81 | -13.72 | -8.86 | -13.73 | -19.90 |
| Weighted Average Shares Outstanding | 212.78 Million | 192.64 Million | 187.46 Million | 176.33 Million | 163.05 Million | 147.5 Million |
| Weighted Average Shares Outstanding (Diluted) | 212.78 Million | 192.64 Million | 187.46 Million | 176.33 Million | 163.05 Million | 147.5 Million |
| Gross Margin | -0.29 | 0.04 | 0.10 | 0.06 | -0.16 | -9.08 |
| EBIT Margin | -2.11 | -0.99 | -1.33 | -5.02 | -6.67 | -8.29 |
| Profit Margin | -2.11 | -0.99 | -2.23 | -4.70 | -7.08 | -10.46 |
| EBITDA | -1.28 Billion | -1.09 Billion | -2.03 Billion | -1.58 Billion | -2.15 Billion | -2.56 Billion |
| Earnings Before Tax Margin | -1.84 | -0.97 | -1.78 | -4.93 | -6.92 | -10.53 |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 100 Million | 144.11 Million | 610.11 Million | 109.55 Million | 208.31 Million | 148.13 Million |
| Cost of Revenue | 281 Million | 183 Million | 787.83 Million | 159.98 Million | 254.94 Million | 189.89 Million |
| Gross Profit | -181 Million | -38.88 Million | -177.71 Million | -50.43 Million | -46.63 Million | -41.76 Million |
| Operating Expenses | 109 Million | 109.16 Million | 943.08 Million | 227.55 Million | 261.87 Million | 344.48 Million |
| Selling, General and Administrative Expenses | 109 Million | -30.3 Million | - | 94.72 Million | 90.58 Million | 110.02 Million |
| Research and Development Expenses | 144.06 Million | 139.46 Million | - | 132.83 Million | 171.29 Million | 234.46 Million |
| Other Expenses | -109.79 Million | - | -4.35 Million | - | - | - |
| Cost and Expenses | 390 Million | 292.16 Million | 1.73 Billion | 387.54 Million | 516.82 Million | 534.38 Million |
| Operating Income | -290 Million | -148.04 Million | -1.12 Billion | -277.99 Million | -308.5 Million | -386.25 Million |
| Interest Expense | 327 Thousand | - | 218 Thousand | - | - | - |
| Income Tax Expense | 540 Thousand | 588 Thousand | 2.42 Million | 612 Thousand | 613 Thousand | 612 Thousand |
| Earnings before Tax | -302 Million | -300.22 Million | -1.28 Billion | -276.05 Million | -309.56 Million | -399.87 Million |
| Net Income | -302 Million | -300.8 Million | -1.28 Billion | -276.66 Million | -310.17 Million | -400.48 Million |
| Earnings Per Share Basic | -1.30 | -1.38 | - | -1.27 | -1.45 | -1.99 |
| Earnings Per Share Diluted | -1.30 | -1.38 | - | -1.27 | -1.45 | -1.99 |
| Weighted Average Shares Outstanding | 232.95 Million | 217.64 Million | 212.78 Million | 217.64 Million | 213.91 Million | 201.01 Million |
| Weighted Average Shares Outstanding (Diluted) | 232.95 Million | 217.64 Million | 212.78 Million | 217.64 Million | 213.91 Million | 201.01 Million |
| Gross Margin | -1.81 | -0.27 | -0.29 | -0.46 | -0.22 | -0.28 |
| EBIT Margin | -2.90 | -1.13 | - | -2.54 | -1.49 | -2.59 |
| Profit Margin | -3.02 | -2.09 | -2.11 | -2.53 | -1.49 | -2.70 |
| EBITDA | -290.26 Million | -162.45 Million | - | -277.99 Million | -309.88 Million | -383.62 Million |
| Earnings Before Tax Margin | -2.90 | -1.03 | -1.84 | -2.54 | -1.48 | -2.61 |
SPK
URBN
FNMFM
MTPS
SKL
017670